论文部分内容阅读
目的 通过检测糖尿病性视网膜病变 (DR)患者血浆、眼内液 (房水、玻璃体 )血管内皮生长因子 (VEGF)含量 ,探讨其在 DR发展变化中的作用。 方法 采用双抗体夹心酶联免疫吸附试验 EL ISA法定量检测患者组及对照组血浆、房水、玻璃体 VEGF含量。 结果 无糖尿病性视网膜病变 (NDR)组血浆 VEGF含量 (34.4 7± 1.76 ) pg/ ml ,单纯型糖尿病性视网膜病变 (BDR)组血浆 VEGF含量 (5 3.93±3.0 8) pg/ ml,增生型糖尿病性视网膜病变 (PDR)组血浆 VEGF含量 (5 3.36± 3.2 8) pg/ ml,对照组血浆VEGF含量 (178.30± 10 .13) pg/ ml,与实验组比较差异均有显著性的意义 (P<0 .0 5 ) ;PDR组房水 VEGF含量 (184 .86± 12 .6 0 ) pg/ ml,对照组房水 VEGF含量 (90 .0 6± 18.32 ) pg/ ml,两者比较差异有显著性的意义 (P<0 .0 5 ) ;PDR组玻璃体 VEGF含量 (74 1.70± 92 .0 2 ) pg/ ml,对照组玻璃体 VEGF含量 (94 .38±2 1.2 1) pg/ ml,两者比较差异有显著性的意义 (P<0 .0 5 )。 PDR组血浆 VEGF与房水、玻璃体 VEGF无相关关系 (P>0 .0 5 ) ,玻璃体 VEGF与糖化血红蛋白 (Hb A1c)有正相关关系 (r=0 .90 6 7,P<0 .0 1)。 结论 糖尿病患者血浆 VEGF含量较正常人低 ,但与房水、玻璃体 VEGF含量无关 ;增生型糖尿病性视网膜病
Objective To investigate the role of vascular endothelial growth factor (VEGF) in the development of DR in patients with diabetic retinopathy (DR). Methods Serum, aqueous humor and vitreous VEGF levels in patients and control groups were quantitatively determined by ELISA using ELISA. Results The plasma levels of VEGF (34.4 7 ± 1.76) pg / ml in non-diabetic retinopathy (NDR), plasma VEGF (5.03 ± 3.08) pg / ml in patients with simple diabetic retinopathy (BDR) Plasma VEGF level (5 3.36 ± 3.2 8) pg / ml in PDR group and plasma VEGF level in control group (178.30 ± 10.13 pg / ml) were significantly different from those in experimental group (P <0.05). The level of VEGF in aqueous humor of PDR group was (184.86 ± 12.60) pg / ml and that of control group was (90.0 ± 18.32) pg / ml (P <0.05). The level of vitreous VEGF in the PDR group was 74.170 ± 92.0 pg / ml, while that in the control group was 94.38 ± 2.112 pg / ml. The difference was significant (P <0.05). There was no significant correlation between plasma VEGF and aqueous humor and vitreous VEGF in PDR group (P> 0.05), and positive correlation between vitreous VEGF and Hb A1c (r = 0.90 6 7, P <0.01 ). Conclusion The plasma VEGF level in diabetic patients is lower than that in normal subjects, but not in aqueous humor and vitreous body. The proliferative diabetic retinopathy